

8. Carman W.F., Trautwein C., van Deursen F.J., Colman K., Dornan E., McIntyre G. et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. *Hepatology*. 1996; 24 (3): 489 – 493.
9. Hsu H.Y., Chang M.H., Ni Y.H., Chen H.L. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. *Gut*. 2004; 53 (10): 1499 – 1503.
10. Oon C.J., Lim G.K., Ye Z., Goh K.T., Tan K.L., Yo S.L. et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. *Vaccine*. 1995; 13 (8): 699 – 702.
11. Oon C.J., Chen W.N. Current aspects of hepatitis B surface antigen mutants in Singapore. *J. Viral. Hepat.* 1998; 5 (Suppl. 2): 17 – 23.
12. Bian T., Yan H., Shen L., Wang F., Zhang S., Cao Y. et al. Change of hepatitis B large surface antigen variants after 13 years universal vaccination program in China. *J. Virol. Nov.* 2013; 87 (22): 12196 – 12206.
13. Semenenko T.A., Nikitina G.Yu., Ptushkin V.V., Yarosh L.V., Kozhevnikova G.M., Polonsky V.O. et al. The prevalence of latent and mutant forms of hepatitis B in patients of hematological departments of a multidisciplinary hospital. *Klinicheskaya mikrobiologiya i antimikrobnaya himoterapiya*. [Clinical Microbiology and Antimicrobial Chemotherapy]. 2016; 18 (1): 56 – 62.
14. Konopleva M.V., Sokolova M.V., Belenikin M.S., Kir'yanov S.A., Shan'ko A.V., Bazhenov A.I. et al. The use of high-performance sequencing (NGS) to identify escape mutations of HBV in patients with malignant blood diseases. Collection of Proceedings of the 9th All-Russian Scientific and Practical Conference with International Participation «Molecular Diagnostics 2017». Москва. 2017; 1: 62 – 63.
15. Wilson J.N., Nokes D.J., Carman W.F. The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? *Vaccine*. 1999; 17 (7 – 8): 973 – 978.
16. Asatryan M.N., Salman E.R., Nikitina G.Yu., Semenenko T.A. The process of spreading hepatitis B in the territories of the federal districts of the Russian Federation (computer modeling). *Epidemiologiya i infektsionnye bolezni. Aktualnye problemi*. [Epidemiology and infectious diseases. Topical issues]. 2015; 2: 4 – 9.
17. Wilson J.N., Nokes D.J., Carman W.F. Current status of HBV vaccine escape variants – a mathematical model of their epidemiology. *J. Viral. Hepat.* 1998; 5 (Suppl. 2): 25 – 30.
18. Asatryan M.N., Salman E.R., Kilikovsky V.V., Kiselev K.V., Sipacheva N.B., Semenenko T.A. Study of the processes of distribution of mutant variants of «vaccinal escape» of the hepatitis B virus by means of a computer epidemiological model. *Epidemiologiya i infektsionnye bolezni. Aktualnye problemi*. [Epidemiology and infectious diseases. Topical issues]. 2013; 6: 34 – 38.
19. Waters J.A., Kennedy M., Voet P., Hauser P., Petre J., Carman W. et al. Loss of the common «A» determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. *J. Clin. Invest.* 1992; 90: 2543 – 2547.
20. Bazhenov A.I., El'gort D.A., Fel'dshero A.A., Budnitskaya P.Z., Nikitina G.I., Khats Yu.S. et al. Detection of antibodies to mutant forms of HBsAg in persons immunized against hepatitis B with vaccines of different subtypes. *Epidemiologiya i Vakcinoprofilaktika*. [Epidemiology and Vaccinal Prevention]. 2011; 5 (60): 49 – 53.
21. Bazhenov A.I., El'gort D.A., Fel'dshero A.A., Budnitskaya P.Z., Nikitina G.I., Khats Yu.S. et al. Comparative evaluation of the activity of naturally-induced anti-HBs or vaccination against various HBsAg variants. *Epidemiologiya i Vakcinoprofilaktika*. [Epidemiology and Vaccinal Prevention]. 2012; 2 (63): 76 – 81.
22. Komatsu H., Inui A., Umetsu S., Tsunoda T., Sogo T., Konishi Y. et al. Evaluation of the G145R mutant of the hepatitis B virus as a minor strain in mother-to-child transmission. *PLoS One*. 2016; 11 (11): e0165674.
23. Noto H., Fujii Y., Takahashi K., Kishimoto S., Mishihiro S. Therapeutic effect of preS2-containing vaccine in an infant infected with a vaccine-escape variant (Thr¹²⁷) of hepatitis B virus. *Int. Hepatol. Commun.* 1997; 6 (3 – 4): 158 – 165.
24. Merck and Co. Inc. HBsAg escape mutant vaccine. EU Patent 0511 855 A1. Publication date 04.11.1992.
25. Thomas H.C., Carman W.F. Hepatitis B vaccine. Patent US 5.639.637. Publication date 17.06.1997.
26. DiaSorin International Inc. Escape mutant of the surface antigen of hepatitis B virus. Patent US 6.172.193 B1. Publication date 09.01.2001.
27. Konopleva M.V., Sokolova M.V., Feldshero A.A., Bazhenov A.I., Suslov A.P. Serological portraying of recombinant antigens of the hepatitis B virus. *Med. Immunologia*. [Med. Immunology]. 2017; 19 (special issue): 150.
28. Konopleva M.V., Borisova V.N., Sokolova M.V., Fel'dshero A.A., Krymsky M.A., Semenenko T.A. Comparative characteristics of antigenic properties of recombinant and native HBs antigens with mutation G145R and evaluation of their immunogenicity. *Voprosi virusologii*. [Problems of Virology]. 2017; 62 (4): 179 – 186.
29. Ben-Porath E., Wands J.R., Marciniak R.A., Wong M.A., Hornstein L., Ryder R. et al. Structural analysis of hepatitis B surface antigen by monoclonal antibodies. *J. Clin. Invest.* 1985; 76 (4): 1338 – 1347.
30. Roohi A., Khoshnoodi J., Zarnani A.H., Shokri F. Epitope mapping of recombinant hepatitis B surface antigen by murine monoclonal antibodies. *Hybridoma (Larchmt)*. 2005; 24 (2): 71 – 77.
31. Bazhenov A.I. Improvement of methods of immunosuppression of HBsAg mutants of hepatitis B virus. Doctorate of med. sci. diss. Moscow; 2009.
32. Rezaee R., Poorebrahim M., Najafi S., Sadeghi S., Pourdast A., Alavian S.M. et al. Impacts of the G145R mutation on the structure and immunogenic activity of the hepatitis B surface antigen: a computational analysis. *Hepat. Mon.* 2016; 16 (7): e39097.
33. Konopleva M.V., Sokolova M.V., Shevlyagina N.V., Bazhenov A.I., Fel'dshero A.A., Krymsky M.A. Morphological analysis of the hepatitis B virus with escape mutations in the S gene of G145R and S143L. *Voprosi virusologii*. [Problems of Virology]. 2017; 62 (3): 119 – 128.
34. Zheng X., Weinberg K.M., Gehrked R., Isogawaa M., Hilken G., Kempera T. et al. Mutant hepatitis B virus surface antigens (HBsAg) are immunogenic but may have a changed specificity. *Virology*. 2004; 329: 454 – 464.
35. Ogata N., Zanetti A.R., Yu M., Miller R.H., Purcell R.H. Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant. *J. Infect. Dis.* 1997; 175 (3): 511 – 523.
36. Ogata N., Cote P.J., Zanetti A.R., Miller R.H., Shapiro M., Gerin J. et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. *Hepatology*. 1999; 30 (3): 779 – 786.
37. Kamili S. Infectivity and vaccination efficacy studies in animal models of HBV S and pol gene mutants. *Antivir. Ther.* 2010; 15 (3 Pt. B): 477 – 585.
38. Crimsky M.A., Borisov I.A., Yakovlev M.S., Agafonov M.O., Ter-Avanesyan M.D., Suslov A.P. et al. The recombinant yeast strain *Hansenula polymorpha* is a producer of the mutant surface antigen of the hepatitis B virus (variants). Patent RU No. 2586513 C1. The date of publication 10/06/2016.
39. Crimsky M.A., Borisov I.A., Yakovlev M.S., Melnikov V.A., Suslov A.P., Semenenko T.A. et al. A method for evaluating the level of antibodies specific for various variants of HBsAg of the hepatitis B virus. Patent No. RU 2616236 C1. Publication Date April 13, 2017.

ERRATA

В статье В.В. Романенко с соавт. «Серологическая характеристика пневмококков, выделенных у детей с диагнозом «Острый средний отит», в Свердловской области», опубликованной в номере 3 (94), была упущена информация о том, что статья подготовлена при финансовой поддержке компании ООО «Пфайзер Инновации». В статье выражена позиция авторов, которая может отличаться от позиции ООО «Пфайзер Инновации».

Pfizer provided financial support to an author for the development of the manuscript. The author's opinion could differ from the official position of the company.